Disc Medicine
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 74
- Market Cap
- -
- Website
- http://www.discmedicine.com
- Introduction
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company was founded in October 2017 and is headquartered in Watertown, MA.
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
- First Posted Date
- 2025-05-22
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Disc Medicine, Inc
- Target Recruit Count
- 20
- Registration Number
- NCT06985147
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
- Conditions
- Erythropoietic Protoporphyria (EPP)X-Linked Protoporphyria (XLP)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Disc Medicine, Inc
- Target Recruit Count
- 150
- Registration Number
- NCT06910358
- Locations
- 🇺🇸
Marvel Clinical Research, Huntington Beach, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸MetroBoston Clinical Partners, Boston, Massachusetts, United States
A Study of DISC-3405 in Healthy Volunteers
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Disc Medicine, Inc
- Target Recruit Count
- 64
- Registration Number
- NCT06050915
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with EPP
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Disc Medicine, Inc
- Target Recruit Count
- 200
- Registration Number
- NCT05883748
- Locations
- 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Einstein Medical Center, Philadelphia, Pennsylvania, United States
Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants with CKD and Anemia
- Conditions
- Chronic Kidney DiseasesAnemia of Chronic Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Disc Medicine, Inc
- Target Recruit Count
- 50
- Registration Number
- NCT05745883
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Rocky Mountain Kidney Care - Lone Tree, Lone Tree, Colorado, United States
🇺🇸Accel Research, DeLand, Florida, United States
Study of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Conditions
- Myelofibrosis; AnemiaMyelofibrosisMyelofibrosis Due to and Following Polycythemia VeraPrimary MyelofibrosisAnemiaPost-essential Thrombocythemia MyelofibrosisMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Disc Medicine, Inc
- Target Recruit Count
- 150
- Registration Number
- NCT05320198
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP
- Conditions
- Erythropoietic Protoporphyria
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Disc Medicine, Inc
- Target Recruit Count
- 75
- Registration Number
- NCT05308472
- Locations
- 🇺🇸
Einstein Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Texas, Galveston, Texas, United States
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Disc Medicine, Inc
- Target Recruit Count
- 42
- Registration Number
- NCT04999527
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States